Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)

Fondazione Italiana Linfomi - ETS

Status: Completed

Conditions: B-Cell Lymphomas

Study type: Observational

Funder types: Other

Identifiers

NCT01478269

IIL_ProDLBCL

Details and patient eligibility

About

This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.

Enrollment: 1,927 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the current World Health Organisation Classification, from 2001 to 2007.
2. Any stage of disease.
3. Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).
4. Age at least 18 years.
5. Availability of tissue biopsy at diagnosis for a possible centralized revision.
6. Availability of data on clinical involvement, laboratory, treatment and follow up.

Exclusion criteria

• None

Trial design

1,927 participants in 1 patient group

Cases of aggressive B-cell lymphoma

Description:

Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy